Vmbook Online ordering

Icons

**Company Overview**

* **Name:** ICON plc

* **Ticker Symbol:** IONS (NASDAQ)

* **Industry:** Contract Research Organization (CRO)

* **Headquarters:** Dublin, Ireland

**Prescription Focus**

ICON is a global CRO that provides a wide range of services to pharmaceutical, biotechnology, and medical device companies. The company's prescription focus includes:

* Clinical research and development

* Regulatory affairs

* Data management and analysis

* Medical writing and publications

**Earnings and Growth**

**Recent Earnings:**

* Q3 2023: Revenue of $1.5 billion, up 14% YoY

* Net income of $214 million, up 20% YoY

* Diluted EPS of $1.18, up 20% YoY

**Growth Metrics:**

* Revenue has grown at a CAGR of 12% over the past 5 years

* Net income has grown at a CAGR of 15% over the past 5 years

* Diluted EPS has grown at a CAGR of 16% over the past 5 years

**Key Financial Indicators:**

* **Market Cap:** $22 billion

* **Price-to-Earnings (P/E) Ratio:** 30x

* **Price-to-Sales (P/S) Ratio:** 5x

* **Debt-to-Equity Ratio:** 0.5x

**Analysts' Outlook**

Analysts are generally bullish on ICON, citing the company's strong growth prospects, global reach, and diversified service offerings. The consensus analyst rating is "Buy" with an average price target of $165.

**Risks**

* Competition from other CROs

* Regulatory changes

* Clinical trial failures

* Currency fluctuations

**Conclusion**

ICON is a leading global CRO with a strong focus on prescription services. The company has a track record of consistent growth and profitability. Analysts are optimistic about ICON's future prospects due to its strong fundamentals and diversified business model.